(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are GENEURO, POLIGHT, and LATECOERE.

The three biggest losers today are CABKA EUR 12W, CABKA EUR 13W, and ORPEA.

Winners today

1. GENEURO (GNRO.PA)

15.55% Price Change

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

CAC 40 ended the session with GENEURO rising 15.55% to €1.10 on Monday while CAC 40 rose 0.18% to €7,246.93.

Earnings Per Share

As for profitability, GENEURO has a trailing twelve months EPS of €-0.54.

Volatility

GENEURO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.03%, a negative 2.68%, and a positive 3.59%.

GENEURO’s highest amplitude of average volatility was 5.03% (last week), 4.00% (last month), and 3.59% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENEURO’s stock is considered to be overbought (>=80).

More news about GENEURO.

2. POLIGHT (PLT.OL)

12.46% Price Change

poLight ASA develops optical lens for consumer devices and industrial applications in Europe, Asia, and the United States. The company's lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes TLens, a tuneable optical lens for autofocus camera applications; Packaged TLens that facilitates integration of a TLens on a fixed-focus camera module; ASIC drivers, which control the supply of variable voltage to Tlens products and makes them to change focus; TLens Silver and TLens Silver Premium devices; and evaluation kits that allows to test and evaluate the optical and electrical performance of the TLens in new products and/or applications. it serves smartphones and wearables, barcode/industrial, augmented reality, medical endoscopy, webcams, and other markets. poLight ASA was founded in 2005 and is headquartered in Skoppum, Norway.

Oslo Børs Benchmark Index_GI ended the session with POLIGHT rising 12.46% to €13.90 on Monday, after five sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI jumped 0.78% to €1,306.38, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-1.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.27%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 42.2%, now sitting on 21.46M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, POLIGHT’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for POLIGHT is 586341 which is 252.87% above its average volume of 166161.

Earnings Before Interest, Taxes, Depreciation, and Amortization

POLIGHT’s EBITDA is 27.29.

More news about POLIGHT.

3. LATECOERE (LAT.PA)

11.31% Price Change

Latécoère S.A. designs, manufactures, assembles, and installs aerostructures and interconnection systems in Europe, the United States, Africa, Asia, and internationally. The company operates through Aerostructures and Interconnection systems segments. It also supplies doors, fuselage, wings, empennage, and connecting rods, as well as manufactures wing sub-assemblies and fuselage components, such as sections, tail cones, front fairings, and watertight bulkheads. In addition, the company offers interconnection systems components comprising of avionics racks, test benches, EWIS and space harnesses; cameras, screens, data transmission solutions; and other electronics. The company was founded in 1917 and is headquartered in Toulouse, France. Latécoère S.A. is a subsidiary of SCP SKN HOLDING I SAS.

CAC 40 ended the session with LATECOERE rising 11.31% to €0.04 on Monday while CAC 40 rose 0.18% to €7,246.93.

Earnings Per Share

As for profitability, LATECOERE has a trailing twelve months EPS of €-8.26.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -311.52%.

More news about LATECOERE.

4. REINET INVESTMENTS (REINA.AS)

11.11% Price Change

Reinet Investments S.C.A. operates as a securitization vehicle in Luxembourg. The company, through its subsidiary, Reinet Fund S.C.A., F.I.S., invests in assets. Reinet Investments Manager S.A. operates as a general partner of Reinet Investments S.C.A. The company was formerly known as Richemont S.A. and changed its name to Reinet Investments S.C.A. in October 2008. Reinet Investments S.C.A. was incorporated in 1979 and is based in Luxembourg City, Luxembourg.

AEX-Index ended the session with REINET INVESTMENTS rising 11.11% to €22.00 on Monday while AEX-Index jumped 0.12% to €759.47.

Earnings Per Share

As for profitability, REINET INVESTMENTS has a trailing twelve months EPS of €-0.66.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, REINET INVESTMENTS’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for REINET INVESTMENTS is 370 which is 54.54% below its average volume of 814.

More news about REINET INVESTMENTS.

5. AVANTIUM (AVTX.AS)

9.74% Price Change

Avantium N.V., a chemical technology company, develops and commercializes renewable chemistry solutions in the Netherlands. The company operates through three segments: Avantium R&D Solutions, Avantium Renewable Chemistries, and Avantium Renewable Polymers. It offers furandicarboxylic acid, a building block for polyethylene furanoate (PEF); and PEF, a plant-based recyclable plastic for use as packaging material. The company also provides catalyst testing systems, including Flowrence that provides catalyst testing and adsorbents. In addition, it offers R&D system, services, and refinery catalyst testing services. Further, the company develops ray technology to produce mono-ethylene glycol from industrial sugars; and dawn technology which converts non-food plant-based feedstock to industrial sugars and lignin. Additionally, it produces polyesters using plantMEG. The company was founded in 2000 and is headquartered in Amsterdam, the Netherlands.

AEX-Index ended the session with AVANTIUM jumping 9.74% to €3.83 on Monday while AEX-Index jumped 0.12% to €759.47.

Earnings Per Share

As for profitability, AVANTIUM has a trailing twelve months EPS of €-0.83.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.25%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 45.8%, now sitting on 20.11M for the twelve trailing months.

Moving Average

AVANTIUM’s value is way above its 50-day moving average of €3.24 and above its 200-day moving average of €3.64.

Volume

Today’s last reported volume for AVANTIUM is 792517 which is 912.45% above its average volume of 78277.

More news about AVANTIUM.

6. SERGEFERRARI GROUP (SEFER.PA)

7.44% Price Change

SergeFerrari Group SA designs, develops, manufactures, and markets composite materials for lightweight architectural and outdoor applications in France and internationally. It provides its products for solar protection, tensile architecture, modular structures, and furniture/marine markets. The company offers solutions for indoor and outdoor blind, and terrace blind and awning; tensile roof and shading structure; indoor and outdoor acoustic treatment; bioclimatic façade, including building construction and renovation; and waterproof breathable membrane applications. It also provides products and solutions for modular structure, visual communication for printed advertisement, protection, environment, and yachting applications. In addition, the company offers outdoor sling seats and membranes for garden furniture; and upholstery for indoor and outdoor furniture. The company was founded in 1973 and is headquartered in Saint-Jean-de-Soudain, France.

CAC 40 ended the session with SERGEFERRARI GROUP jumping 7.44% to €7.22 on Monday while CAC 40 rose 0.18% to €7,246.93.

Earnings Per Share

As for profitability, SERGEFERRARI GROUP has a trailing twelve months EPS of €0.88.

PE Ratio

SERGEFERRARI GROUP has a trailing twelve months price to earnings ratio of 8.2. Meaning, the purchaser of the share is investing €8.2 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.9%.

More news about SERGEFERRARI GROUP.

7. AKER HORIZONS (AKH.OL)

6.6% Price Change

Aker Horizons ASA, through its subsidiaries, develops and invests in a portfolio of companies in the renewable energy and green technology comprising private and public companies worldwide. It sources, develops, structures, builds, and operates wind and solar power assets; and develops, builds, owns, and operates clean hydrogen production at industrial scale. The company also provides products, technology, and solutions within the field of carbon capture, utilization, and storage. In addition, it offers products and services to the hydropower industry; designs and delivers superconducting systems; and produces silicon materials. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Horizons ASA operates as a subsidiary of Aker Capital AS.

Oslo Børs Benchmark Index_GI ended the session with AKER HORIZONS rising 6.6% to €4.20 on Monday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.78% to €1,306.38, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, AKER HORIZONS has a trailing twelve months EPS of kr-9.91.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.14%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKER HORIZONS’s stock is considered to be overbought (>=80).

Moving Average

AKER HORIZONS’s worth is way under its 50-day moving average of kr6.41 and way below its 200-day moving average of kr10.38.

More news about AKER HORIZONS.

8. VIVORYON (VVY.AS)

6.49% Price Change

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

AEX-Index ended the session with VIVORYON rising 6.49% to €8.20 on Monday while AEX-Index rose 0.12% to €759.47.

Earnings Per Share

As for profitability, VIVORYON has a trailing twelve months EPS of €-1.12.

More news about VIVORYON.

9. AKASTOR (AKAST.OL)

6.36% Price Change

Akastor ASA operates as an oilfield services investment company in Norway, the United Kingdom, Denmark, Australia, and internationally. The company offers vessel-based subsea well construction and intervention services to the oil and gas industry. It also provides well design and drilling project management services; reservoir and field management services; and rig procurement, tailored training, software, and technical manpower services, as well as well and reservoir consultancy services. In addition, the company offers a range of offshore drilling equipment products and packages. It owns five offshore vessels. Akastor ASA was founded in 1841 and is based in Bærum, Norway.

Oslo Børs Benchmark Index_GI ended the session with AKASTOR jumping 6.36% to €11.04 on Monday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI jumped 0.78% to €1,306.38, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, AKASTOR has a trailing twelve months EPS of kr-1.83.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.13%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.5%, now sitting on 1.07B for the twelve trailing months.

More news about AKASTOR.

10. IDEX BIOMETRICS (IDEX.OL)

6.25% Price Change

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with IDEX BIOMETRICS rising 6.25% to €0.43 on Monday while Oslo Børs Benchmark Index_GI rose 0.78% to €1,306.38.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-0.22.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -199.48%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.4%, now sitting on 4.72M for the twelve trailing months.

Yearly Top and Bottom Value

IDEX BIOMETRICS’s stock is valued at kr0.43 at 21:40 EST, way under its 52-week high of kr1.37 and way above its 52-week low of kr0.36.

More news about IDEX BIOMETRICS.

Losers Today

1. CABKA EUR 12W (DSCW2.AS)

-60% Price Change

AEX-Index ended the session with CABKA EUR 12W dropping 60% to €0.02 on Monday while AEX-Index jumped 0.12% to €759.47.

Yearly Top and Bottom Value

CABKA EUR 12W’s stock is valued at €0.02 at 21:40 EST, way below its 52-week low of €0.06.

More news about CABKA EUR 12W.

2. CABKA EUR 13W (DSCW3.AS)

-40% Price Change

AEX-Index ended the session with CABKA EUR 13W sliding 40% to €0.03 on Monday, after five successive sessions in a row of losses. AEX-Index jumped 0.12% to €759.47, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

More news about CABKA EUR 13W.

3. ORPEA (ORP.PA)

-16.67% Price Change

ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.

CAC 40 ended the session with ORPEA falling 16.67% to €0.41 on Monday while CAC 40 jumped 0.18% to €7,246.93.

Earnings Per Share

As for profitability, ORPEA has a trailing twelve months EPS of €-4.11.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -445.48%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10.7%, now sitting on 4.93B for the twelve trailing months.

More news about ORPEA.

4. OCEANTEAM (OTS.OL)

-12.16% Price Change

Oceanteam ASA operates as a subsea and offshore services company in Europe. It provides equipment for offshore cable laying, umbilical installations, and on- and offshore storage and transport. The company also rents turntables, tensioners, reels, demountable turntable systems, and other cable handling and storage equipment, as well as offers cable and umbilical storage, and handling solutions. It serves renewable energy, and oil and gas industries. The company was formerly known as Oceanteam Shipping ASA and changed its name to Oceanteam ASA in December 2015. Oceanteam ASA was incorporated in 2005 and is headquartered in Bærum, Norway.

Oslo Børs Benchmark Index_GI ended the session with OCEANTEAM falling 12.16% to €1.30 on Monday while Oslo Børs Benchmark Index_GI jumped 0.78% to €1,306.38.

Earnings Per Share

As for profitability, OCEANTEAM has a trailing twelve months EPS of kr-0.32.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.62%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 33.3%, now sitting on 70k for the twelve trailing months.

More news about OCEANTEAM.

5. ECONOCOM GROUP (ECONB.BR)

-9.56% Price Change

Econocom Group SE conceives, finances, and facilitates the digital transformation of large firms and public organizations. It offers financing solutions for the administrative and financial management of the ICT and digital assets of the businesses. The company provides consulting, infrastructure management, applications development, and digital solutions and systems integration, as well as design and roll-out solutions; and sells hardware and software, such as PCs, tablets, servers, printers, licences, digital objects, etc. It operates in 16 countries, including Europe, Morocco, Brazil, Mexico, Canada, and the United States. The company sells its products and services under the Econocom brand name. Econocom Group SE was incorporated in 1982 and is based in Puteaux, France.

BEL 20 ended the session with ECONOCOM GROUP dropping 9.56% to €2.27 on Monday, following the last session’s upward trend. BEL 20 rose 0.01% to €3,534.77, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, ECONOCOM GROUP has a trailing twelve months EPS of €0.29.

PE Ratio

ECONOCOM GROUP has a trailing twelve months price to earnings ratio of 7.83. Meaning, the purchaser of the share is investing €7.83 for every euro of annual earnings.

More news about ECONOCOM GROUP.

6. BENEVOLENTAI (BAI.AS)

-8.15% Price Change

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI dropping 8.15% to €0.62 on Monday while AEX-Index jumped 0.12% to €759.47.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.47.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.97%.

More news about BENEVOLENTAI.

7. CARASENT (CARA.OL)

-6.61% Price Change

Carasent ASA provides cloud-based medical record services to the health care industry in the Nordic region. The company offers Webdoc, a digital electronic health record (EHR) system; Vårdrummet, a digital platform for communication between patients and therapists, as well as care givers; and Ad Curis, a journal and professional system that delivers forward-thinking services to rehabilitation, substance abuse treatment, and mental health care, as well as organizations within upbringing and preventive works. It also provides Metodika EPM, a solution for medium sized private clinics and hospitals; Medrave M4, a program that offers healthcare professionals with an overview of the patient treatment group; Confrere, a video solution for physicians; and Plustoo, a software solution that collects, analyses, and visualizes data, as well as enables occupational health providers, employers, and employees to collaborate for healthy and sustainable work environment. In addition, the company provides Ad Voca; and Ad Opus, a system that structures work processes to follow-up participants in a course of measures for companies that work with inclusion into working life. Carasent ASA was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. The company was founded in 1997 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with CARASENT falling 6.61% to €10.74 on Monday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.78% to €1,306.38, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, CARASENT has a trailing twelve months EPS of kr-0.8.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.05%.

More news about CARASENT.

8. NORTHERN DRILLING (NODL.OL)

-6.36% Price Change

Northern Drilling Ltd. operates as an offshore drilling contractor to the oil and gas industry. The company primarily engages in acquiring and operating offshore drilling assets, as well as involved in drilling in ultra-deep water environments. Northern Drilling Ltd. was incorporated in 2017 and is based in Hamilton, Bermuda.

Oslo Børs Benchmark Index_GI ended the session with NORTHERN DRILLING dropping 6.36% to €1.11 on Monday while Oslo Børs Benchmark Index_GI jumped 0.78% to €1,306.38.

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-6.06.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.22%.

More news about NORTHERN DRILLING.

9. PCI BIOTECH HOLD (PCIB.OL)

-5.78% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD sliding 5.78% to €2.12 on Monday while Oslo Børs Benchmark Index_GI jumped 0.78% to €1,306.38.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.

Volume

Today’s last reported volume for PCI BIOTECH HOLD is 437556 which is 36.83% below its average volume of 692666.

Revenue Growth

Year-on-year quarterly revenue growth declined by 84.4%, now sitting on 2.79M for the twelve trailing months.

Volatility

PCI BIOTECH HOLD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.07%, a positive 1.55%, and a positive 7.81%.

PCI BIOTECH HOLD’s highest amplitude of average volatility was 4.20% (last week), 9.29% (last month), and 7.81% (last quarter).

More news about PCI BIOTECH HOLD.

10. ALFEN (ALFEN.AS)

-5.66% Price Change

Alfen N.V., through its subsidiaries, designs, engineers, develops, produces, and sells products, systems, and services related to the electricity grid. The company offers smart grid solutions, including secondary transformer substations for grid operators, devices for grid automation, and proprietary back-end systems for remote management and control of electricity grids, as well as micro-grids; and supplementary offerings to grid connect amongst others PV farms, EV fast-charging hubs, and industrial companies. It also provides energy storage systems comprising stationary and mobile battery energy storage solutions for load balancing, peak shaving, grid frequency control, and energy trading solutions, as well as embedded software and back-office solutions that enables remote monitoring, control, and support for storage applications. In addition, the company offers smart and connected electric vehicle chargers for use at the home, retail, workplace, and public locations, as well as an online management platform for charging infrastructure and standardized solutions for smart charging, load balancing, charging hubs, and plug and charge functionalities. It operates primarily in the Netherlands, Belgium, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden, Switzerland, Austria, the United Kingdom, and the rest of Europe. The company was founded in 1937 and is headquartered in Almere, the Netherlands.

AEX-Index ended the session with ALFEN dropping 5.66% to €45.00 on Monday, following the last session’s upward trend. AEX-Index jumped 0.12% to €759.47, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, ALFEN has a trailing twelve months EPS of €1.73.

PE Ratio

ALFEN has a trailing twelve months price to earnings ratio of 26.01. Meaning, the purchaser of the share is investing €26.01 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.01%.

Volatility

ALFEN’s last week, last month’s, and last quarter’s current intraday variation average was 1.59%, 2.32%, and 2.92%.

ALFEN’s highest amplitude of average volatility was 1.73% (last week), 3.75% (last month), and 2.92% (last quarter).

Yearly Top and Bottom Value

ALFEN’s stock is valued at €45.00 at 21:40 EST, way under its 52-week high of €96.14 and way above its 52-week low of €27.31.

Moving Average

ALFEN’s worth is way above its 50-day moving average of €37.74 and way below its 200-day moving average of €59.58.

More news about ALFEN.

Stay up to date with our winners and losers daily report